Haploidentical Hematopoietic Stem Cell Allogeneic Transplantation With High Dose Post Transplantation Cyclophosphamide For Patients Over 60 Years Of Age

Recent advances in the field of haploidentical hematopoietic stem cell transplantation (Haplo-SCT) allowed larger access to allogeneic treatment in absence of HLA-matched donor. Indeed, former limitations associated with HLA disparity could be overcome by the use of post-transplant cyclophosphamide (PT-Cy) as part of GVHD prophylaxis. Low toxicity observed after PT-Cy Haplo-SCT enabled its diffusion to older patients who are disproportionally affected with hematological malignancies. The aim of our study was to assess the outcome after Haplo-SCT in this specific setting of elderly patients.